RITUXIMAB, HIGH DOSE CYCLOPHOSPHAMIDE, AND GM-CSF BASED IMMUNOTHERAPY

基于利妥昔单抗、高剂量环磷酰胺和 GM-CSF 的免疫治疗

• 批准号: 7604664
• 负责人: YVETTE L. KASAMON
• 金额: $ 0.14万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604664
• 关键词: AIDS-Related Hodgkin' s Lymphoma; Affect; Antibodies; Cancer Vaccines; Computer Retrieval of Information on Scientific Projects Database; Cyclophosphamide; Disease; Dose; Funding; Grant; Granulocyte-Macrophage Colony-Stimulating Factor; High Dose Chemotherapy; Hodgkin Disease; Human Herpesvirus 4; Immune system; Immunologics; Immunotherapy; Institution; Lymphoma; Monitor; Non-Hodgkin' s Lymphoma; Patients; Proteins; Relapse; Reporter; Research; Research Personnel; Resources; Risk; Safety; Source; Stem cells; System; United States National Institutes of Health; Vaccines; base; chemotherapy; novel vaccines; response; rituximab

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. New treatments are needed for patients with relapsed or poor-risk Hodgkin's lymphoma. A variety of immunotherapies may be promising. Recent discoveries suggest that rituximab, an antibody used for non-Hodgkin's lymphomas, may also be effective in Hodgkin's, in part by attacking the "stem cell" that gives rise to the disease. Tumor vaccines are another treatment strategy, but how these are affected by rituximab or chemotherapy is largely unknown. This study combines rituximab, high doses of chemotherapy, and a new tumor vaccine for patients with relapsed Hodgkin's lymphoma. The vaccine expresses several proteins that are also found in Hodgkin's lymphomas. The effects of the vaccine on the immune system will be studied in detail, and the results will be extended to other studies of lymphoma immunotherapy. Patients with relapsed, non-HIV-associated Hodgkin's lymphoma are potentially eligible. Up to 20 patients will receive the vaccine. Primary objectives To determine the safety and tolerability of rituximab in combination with high dose cyclophosphamide and GM-CSF based immunotherapy with a novel vaccine (KGEL) for relapsed HL. To describe the immunologic responses to this vaccine following high dose therapy. To evaluate the utility of an EBV reporter system for monitoring cellular vaccine responses.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 患有复发或风险较差的霍奇金淋巴瘤的患者需要新的治疗方法。 各种免疫疗法可能是有希望的。 最近的发现表明，利妥昔单抗是一种用于非霍奇金淋巴瘤的抗体，也可能在霍奇金的抗体中有效，部分是通过攻击引起该疾病的“干细胞”。 肿瘤疫苗是另一种治疗策略，但是这些策略如何受到利妥昔单抗或化学疗法的影响。 这项研究结合了利妥昔单抗，高剂量的化疗和新的肿瘤疫苗，用于复发性霍奇金淋巴瘤患者。 该疫苗表达了几种在霍奇金淋巴瘤中也发现的蛋白质。 该疫苗对免疫系统的影响将进行详细研究，结果将扩展到其他有关淋巴瘤免疫疗法的研究。 患有复发，非HIV相关的Hodgkin淋巴瘤的患者可能符合条件。 多达20名患者将接受疫苗。 主要目标 确定利妥昔单抗与高剂量环磷酰胺和基于GM-CSF的免疫疗法的安全性和耐受性，并用新型的疫苗（KGEL）用于复发HL。 描述高剂量治疗后对这种疫苗的免疫反应。 评估EBV报告基因系统以监测细胞疫苗反应的效用。